JP2013531993A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531993A5
JP2013531993A5 JP2013515568A JP2013515568A JP2013531993A5 JP 2013531993 A5 JP2013531993 A5 JP 2013531993A5 JP 2013515568 A JP2013515568 A JP 2013515568A JP 2013515568 A JP2013515568 A JP 2013515568A JP 2013531993 A5 JP2013531993 A5 JP 2013531993A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
influenza
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531993A (ja
JP6050747B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040982 external-priority patent/WO2011160083A1/en
Publication of JP2013531993A publication Critical patent/JP2013531993A/ja
Publication of JP2013531993A5 publication Critical patent/JP2013531993A5/ja
Application granted granted Critical
Publication of JP6050747B2 publication Critical patent/JP6050747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515568A 2010-06-17 2011-06-17 インフルエンザ受動免疫化に有用な抗体 Active JP6050747B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US61/355,978 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US61/443,103 2011-02-15
US201161445455P 2011-02-22 2011-02-22
US61/445,455 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (3)

Publication Number Publication Date
JP2013531993A JP2013531993A (ja) 2013-08-15
JP2013531993A5 true JP2013531993A5 (enExample) 2014-07-31
JP6050747B2 JP6050747B2 (ja) 2016-12-21

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515568A Active JP6050747B2 (ja) 2010-06-17 2011-06-17 インフルエンザ受動免疫化に有用な抗体

Country Status (12)

Country Link
US (1) US10676520B2 (enExample)
EP (1) EP2582721B1 (enExample)
JP (1) JP6050747B2 (enExample)
KR (1) KR101849738B1 (enExample)
CN (2) CN103209994B (enExample)
AU (2) AU2011268072C1 (enExample)
BR (1) BR112012032185A2 (enExample)
CA (1) CA2839421C (enExample)
DK (1) DK2582721T3 (enExample)
ES (1) ES2687706T3 (enExample)
RU (1) RU2635999C2 (enExample)
WO (1) WO2011160083A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6371222B2 (ja) 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
MX2015005860A (es) 2012-11-13 2015-08-10 Genentech Inc Anticuerpos de antihemaglutinina y metodo de uso.
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
WO2015120097A2 (en) 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) * 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EP3119802B1 (en) * 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
JP2019529345A (ja) * 2016-07-14 2019-10-17 バイオアークティック アクティエボラーグ 脳送達タンパク質
CN111989115A (zh) * 2017-12-29 2020-11-24 财团法人生物技术开发中心 针对流感的通用疫苗
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
JP2006519775A (ja) 2003-03-07 2006-08-31 メルク エンド カムパニー インコーポレーテッド インフルエンザウイルスワクチン
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
WO2005007697A1 (ja) * 2003-07-23 2005-01-27 Fujirebio Inc. 抗インフルエンザa型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP2009537147A (ja) * 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ, エルエルシー インフルエンザウイルスに対する中和抗体
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN101970483A (zh) * 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
JP2011516423A (ja) * 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ, エルエルシー ウイルス抗原に対する中和分子
EP2313433A2 (en) * 2008-07-25 2011-04-27 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CL2009001735A1 (es) * 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
CN102292350A (zh) 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
EA029198B1 (ru) * 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
CA2807664A1 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Similar Documents

Publication Publication Date Title
JP2013531993A5 (enExample)
JP6325451B2 (ja) A型インフルエンザに特異的な抗体
CN104892753B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
Lee et al. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies
RU2013102073A (ru) Антитела, подходящие для пассивной иммунизации против гриппа
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP6371222B2 (ja) インフルエンザの受動免疫用抗体
JP2011528901A5 (enExample)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2014237714A5 (enExample)
JP2016503413A5 (enExample)
JP2010502207A5 (enExample)
JP2011528902A5 (enExample)
JP2015522252A5 (enExample)
JP2012526839A5 (enExample)
JP2013501807A5 (enExample)
US10610587B2 (en) Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
CN105985433B (zh) 针对h7n9亚型禽流感病毒的全人源单克隆抗体及应用
CN111094335A (zh) 广泛中和的抗流感单克隆抗体及其用途
CN101993492B (zh) 抗H5N1型高致病性禽流感scFv抗体及其应用
CN107216387B (zh) 一种b型流感病毒广谱中和抗体、其制备方法及应用
Wu et al. Allosteric Neutralization by Human H7N9 Antibodies
Jia et al. Allosteric Neutralization by Human H7N9 Antibodies
Voronina et al. Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection
Wyrzucki Characterization of influenza a neutralizing, heterosubtypic antibodies isolated with a newly developed antigen